Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients

There are limited data regarding the feasibility of transitioning from intravenous prostacyclins to selexipag in pulmonary arterial hypertension patients. We present a case series of successful transitions from intravenous prostacyclins to selexipag in the majority of carefully selected five stable...

Descripción completa

Detalles Bibliográficos
Autores principales: Aldweib, Nael, Verlinden, Nathan J., Kassis-George, Hayah, Raina, Amresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504235/
https://www.ncbi.nlm.nih.gov/pubmed/34646497
http://dx.doi.org/10.1177/20458940211036623
_version_ 1784581290396221440
author Aldweib, Nael
Verlinden, Nathan J.
Kassis-George, Hayah
Raina, Amresh
author_facet Aldweib, Nael
Verlinden, Nathan J.
Kassis-George, Hayah
Raina, Amresh
author_sort Aldweib, Nael
collection PubMed
description There are limited data regarding the feasibility of transitioning from intravenous prostacyclins to selexipag in pulmonary arterial hypertension patients. We present a case series of successful transitions from intravenous prostacyclins to selexipag in the majority of carefully selected five stable pulmonary arterial hypertension patients using a standardized protocol in the outpatient setting.
format Online
Article
Text
id pubmed-8504235
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-85042352021-10-12 Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients Aldweib, Nael Verlinden, Nathan J. Kassis-George, Hayah Raina, Amresh Pulm Circ Case Report There are limited data regarding the feasibility of transitioning from intravenous prostacyclins to selexipag in pulmonary arterial hypertension patients. We present a case series of successful transitions from intravenous prostacyclins to selexipag in the majority of carefully selected five stable pulmonary arterial hypertension patients using a standardized protocol in the outpatient setting. SAGE Publications 2021-10-09 /pmc/articles/PMC8504235/ /pubmed/34646497 http://dx.doi.org/10.1177/20458940211036623 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Aldweib, Nael
Verlinden, Nathan J.
Kassis-George, Hayah
Raina, Amresh
Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients
title Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients
title_full Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients
title_fullStr Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients
title_full_unstemmed Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients
title_short Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients
title_sort transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504235/
https://www.ncbi.nlm.nih.gov/pubmed/34646497
http://dx.doi.org/10.1177/20458940211036623
work_keys_str_mv AT aldweibnael transitionfromparenteralprostacyclinstoselexipagsafetyandfeasibilityinselectedpatients
AT verlindennathanj transitionfromparenteralprostacyclinstoselexipagsafetyandfeasibilityinselectedpatients
AT kassisgeorgehayah transitionfromparenteralprostacyclinstoselexipagsafetyandfeasibilityinselectedpatients
AT rainaamresh transitionfromparenteralprostacyclinstoselexipagsafetyandfeasibilityinselectedpatients

Ejemplares similares